Moreover, their results revealed that drug-sensitive lung cancer cells obtained gemcitabine resistance after taking up exosomal miR-222-3p, whose target gene was proven to be suppressor of cytokine signaling 3 (SOCS3). The gene discussed is SOCS3; the disease is lung carcinoma.